Brokers Set Expectations for Clorox's Q4 Earnings (NYSE:CLX)

The Clorox Company (NYSE:CLX - Free Report) - Research analysts at Zacks Research boosted their Q4 2025 earnings per share estimates for shares of Clorox in a research note issued on Monday, May 19th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.23 per share for the quarter, up from their previous estimate of $2.14. The consensus estimate for Clorox's current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox's Q1 2026 earnings at $1.52 EPS, Q2 2026 earnings at $1.51 EPS, Q3 2026 earnings at $1.57 EPS, FY2026 earnings at $6.71 EPS, Q1 2027 earnings at $1.62 EPS, Q2 2027 earnings at $1.71 EPS and Q3 2027 earnings at $1.70 EPS.

Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same period in the prior year, the firm earned $1.71 EPS. The business's revenue for the quarter was down 8.0% compared to the same quarter last year.

Several other equities analysts have also recently issued reports on the company. Barclays lowered their price target on Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research report on Wednesday, May 7th. Morgan Stanley lowered their target price on Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Citigroup decreased their price target on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a research note on Monday, April 14th. JPMorgan Chase & Co. reduced their target price on shares of Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Finally, Wells Fargo & Company reduced their target price on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $151.23.

Clorox Stock Performance

NYSE:CLX traded up $0.07 during midday trading on Wednesday, reaching $130.97. 1,243,078 shares of the company traded hands, compared to its average volume of 1,333,942. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60. The company has a fifty day moving average price of $139.64 and a 200 day moving average price of $152.24. The firm has a market capitalization of $16.14 billion, a price-to-earnings ratio of 35.78, a price-to-earnings-growth ratio of 2.62 and a beta of 0.60. Clorox has a twelve month low of $127.60 and a twelve month high of $171.37.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Integral Investment Advisors Inc. grew its position in shares of Clorox by 4.1% in the 4th quarter. Integral Investment Advisors Inc. now owns 1,718 shares of the company's stock worth $279,000 after buying an additional 67 shares during the last quarter. Sonora Investment Management Group LLC grew its stake in shares of Clorox by 2.5% in the first quarter. Sonora Investment Management Group LLC now owns 2,940 shares of the company's stock worth $433,000 after acquiring an additional 72 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Clorox by 0.6% in the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,266 shares of the company's stock worth $1,953,000 after acquiring an additional 73 shares during the last quarter. Horizon Investments LLC increased its holdings in shares of Clorox by 4.4% during the first quarter. Horizon Investments LLC now owns 1,768 shares of the company's stock valued at $258,000 after acquiring an additional 75 shares in the last quarter. Finally, Sfmg LLC grew its holdings in shares of Clorox by 2.8% during the first quarter. Sfmg LLC now owns 2,780 shares of the company's stock valued at $409,000 after buying an additional 76 shares during the last quarter. Institutional investors own 78.53% of the company's stock.

Insider Activity at Clorox

In related news, Director Pierre R. Breber bought 4,000 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the acquisition, the director now directly owns 4,000 shares of the company's stock, valued at $546,280. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.57% of the stock is owned by insiders.

Clorox Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 9th. Investors of record on Wednesday, April 23rd were paid a $1.22 dividend. The ex-dividend date of this dividend was Wednesday, April 23rd. This represents a $4.88 dividend on an annualized basis and a yield of 3.73%. Clorox's dividend payout ratio is presently 87.61%.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.